CymaBay Therapeutics (NASDAQ:CBAY) has announced positive results from its Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC). As quoted in the press release: These data are being presented today at The International Liver Congress™ 2019 of the European Association for the Study of Liver (EASL) in Vienna, Austria, along with three … Continued
The post CymaBay Therapeutics Presents Positive Phase 2 Data for Seladelpar appeared first on Investing News Network.
Original Article: CymaBay Therapeutics Presents Positive Phase 2 Data for Seladelpar